CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Gilead’s Livdelzi meets ALP normalization endpoint in 75.4% of patients in Phase 3 PBC trial

By Public Technologies
  • Gilead Sciences reported Phase 3 IDEAL results showing Livdelzi normalized a key liver disease marker more often than placebo in primary biliary cholangitis.
  • The trial evaluated second-line treatment in patients with mildly elevated alkaline phosphatase levels, a population largely excluded from previous pivotal trials.
  • No new safety concerns emerged; adverse event rates were generally similar between treatment groups.
  • Gilead is discussing the results with global regulators.
  • Results will be presented at The Liver Meeting in Denver, November 5-9, 2026; publication has been accepted by the Journal of Hepatology.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261104536872) on November 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.